![]() |
¿¬°£Á¤º¸ ¼ºñ½º
»óǰÄÚµå
1262973
¼¼°èÀÇ Ç×ü ½ÃÀå : Ç¥Àû, ±â¼ú, ÆÄÀÌÇÁ¶óÀÎ µ¥ÀÌÅͺ£À̽º(¿¬°£ ±¸µ¶)Antibody Target, Technology & Pipeline Database: 1-Year Subscription |
º» º¸°í¼´Â Ç×ü µ¥ÀÌÅͺ£À̽º·Î¼ ½ÃÀå ¹× ¿¬±¸ °³¹ß Áß Ç×ü Ä¡·áÁ¦¿¡ °üÇÑ 6,231°Ç ÀÌ»óÀÇ ÇÁ·ÎÁ§Æ® Á¤º¸¸¦ ¿Â¶óÀÎÀ¸·Î ÀÔ¼öÇÒ ¼ö ÀÖ½À´Ï´Ù. ¹Ì¸® Á¤ÀÇµÈ Ç¥Àû ¹× ±â¼úÀÇ ½ºÅ©·Ñ´Ù¿î ¸Þ´º¿¡¼ °ü½É ÀÖ´Â ÇÁ·ÎÁ§Æ®¸¦ ½±°Ô ¼±ÅÃÇÒ ¼ö ÀÖ½À´Ï´Ù.
Subscription to La Merie Publishing's proprietary Antibody Database provides online access to information about more than 6,231 project entries for therapeutic antibodies on the market and in research & development. Pre-established and free search functions allow to identify antibodies according to their
Each project is specified for its Target, Therapeutic Area and R&D Phase. Use of the R&D database of therapeutic antibodies is intuitive. Data sets of interest can be printed and exported as reports in Excel or Word format. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. Sales figures of major therapeutic antibodies on the market are provided. An advanced search function allows to combine search parameters. A scroll down menu for predefined targets and technologies conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase or company name.
Prerequisite: Internet access.
Purchase of the subscription provides a 1-year online access to the data of the Antibody Target, Technology & Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.